Quadracel®
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine

NOW AVAILABLE FROM QUADRACEL®

PREFILLED SYRINGES

AND A CHANGE IN FORMULATION

CHANGE IN FORMULATION. SAME PROFILE.

INDICATION

Quadracel is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).



WHAT HAS CHANGED?

Quadracel is available in prefilled syringes made without natural rubber latex. Quadracel has also changed the source of IPV antigen from MRC-5-derived IPV (mIPV) to IPV that is derived from Vero cells (vIPV), which aligns with that contained in the Sanofi Pasteur single-entity IPV vaccine.[1,2]

HOW DOES THIS IMPACT QUADRACEL?

This formulation of Quadracel retains the same dosing schedule, indication, safety, and immunogenicity data as the Quadracel formulation that is currently used.[1,2] Compared with single-entity alternatives, with Quadracel you can complete a patient's series of DTaP and IPV vaccination with one fewer injection.[1-4] Also, by using Sanofi Pasteur DTaP antigen-containing vaccines and Quadracel together, you can have continuity of DTaP antigens across the 5-dose series.[1,5,6]

See next page to learn what this means for you.

IMPORTANT SAFETY INFORMATION

Contraindications to vaccination with Quadracel include: a severe allergic reaction (e.g., anaphylaxis) to any ingredient of Quadracel or following any other diphtheria toxoid-, tetanus toxoid-, or pertussis antigen-containing vaccine, or inactivated poliovirus vaccine; encephalopathy within 7 days of a previous dose of a pertussis antigen-containing vaccine that is not attributable to another identifiable cause; or a progressive neurologic disorder.

Please see continued Important Safety Information on the back of this piece. Please see the full Prescribing Information for Quadracel (49281-562-10 and 49281-564-10/15).

Quadracel is part of a larger Sanofi Pasteur pediatric portfolio committed to helping protect your eligible patients against vaccine-preventable disease.[1]

ORDER NOW >

WHAT'S THE DIFFERENCE?[1,2]

UPDATED Quadracel formulated with Vero cell-derived IPV[2]

Indication			No change
Presentation			**Now available in both prefilled syringes and vials**
DTaP component			No change
IPV component			**Sourced from Vero cell-line manufacturing process**
Immunogenicity data*			No change
Safety*			No change
CPT code (reimbursement)			No change
National Drug Code (NDC)	Quadracel Vials	Carton	49281-564-10
		Vial	49281-564-58
	Quadracel Syringes	Carton	49281-564-15
		Syringe	49281-564-88

*The safety and immunogenicity data are based on IPV antigen grown in MRC-5 cell line.[1,2]

Ask your Sanofi Pasteur sales representative to learn more and to place an order for Sanofi Pasteur vaccines.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Carefully consider benefits and risks before administering Quadracel to persons with a history of: fever ≥105°F, hypotonic-hyporesponsive episode, or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures within 3 days after a previous pertussis antigen-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Quadracel or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.

The most common local and systemic adverse reactions to Quadracel include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.

Vaccination with Quadracel may not protect all individuals.

Please see the full Prescribing Information for Quadracel (49281-562-10 and 49281-564-10/15).

Please use this resource to help educate staff in your office about the updated formulation of Quadracel. Please ensure the new NDCs are loaded into your Electronic Health Records system before administration. If you have any additional questions, please contact your Quadracel representative.

References: 1. Quadracel [Prescribing Information]. NDC No. 49281-564-10/15. Swiftwater, PA: Sanofi Pasteur Inc. **2.** Quadracel [Prescribing Information]. NDC No. 49281-562-10. Swiftwater, PA: Sanofi Pasteur Inc. **3.** Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Accessed February 8, 2022. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html **4.** Mosley JF II, Smith LL, Parke CK, Brown JA, LaFrance JM, Clark PK. Quadracel: vaccination against diphtheria, tetanus, pertussis, and poliomyelitis in children. *P T*. 2016;41(4):238-253. **5.** Liang J, Wallace G, Mootrey G. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. *MMWR Morb Mortal Wkly Rep*. 2015;64(34):948-949. doi:10.15585/mmwr.mm6434a5 **6.** Data on file. Internal acellular pertussis antigen statement. Swiftwater, PA: Sanofi Pasteur Inc.

SANOFI PASTEUR. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofi.us

SANOFI PASTEUR